DarshanTalks Podcast

Send us Fan Mail

AI voice tech might be the next big privacy risk for pharma marketers, and lawsuits are already in motion. In this episode of Darshan Talks, we dive into the legal challenges surrounding AI-powered voice tools in healthcare marketing, especially under California’s strict privacy laws.

A federal court ruling in Ambrose v. Google suggests that recording conversations without explicit real-time consent may be illegal. This could impact pharma companies using AI voice assistants, Alexa skills, voice bots, and patient support apps. If your tech processes speech without proper disclosures, you might be violating the California Invasion of Privacy Act (CIPA)—a law with $5,000 in statutory damages per violation.

For large pharma brands, non-compliance could lead to multimillion-dollar class action lawsuits. Burying consent deep in a privacy policy won’t cut it anymore—courts are demanding clear, real-time disclosure. To stay ahead, pharma marketers must audit their tech stack, collaborate with privacy law experts, and push vendors to meet compliance standards.

The future of pharma marketing is controversial, and the brands that innovate responsibly will thrive. Contact the Kulkarni Law Firm to audit your voice marketing stack before the lawsuits start piling up.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Event details- https://www.linkedin.com/events/protectingsponsors-fraudandcomp7318667647213002752/comments/

Registration Link- https://us02web.zoom.us/meeting/register/KhsVL6C6Tg6KKNDRHYTEKA

In this kickoff conversation, Darshan Kulkarni and Edye Edens introduce a candid new series exploring how legal and compliance professionals approach clinical research differently—but with a shared mission. The idea was born at the Save Our Sites event, where they realized they often take distinct, yet complementary, paths to solve the same problems.

Edye draws from her deep operational and academic background, including experience with the ORI and FDA, and focuses on making complex issues relatable and engaging. Darshan brings a broader regulatory lens—from sponsor, CRO, and site perspectives—and specializes in enforcement expectations from DOJ, OIG, OCR, and FDA. Together, they balance legal precision with practical implementation.

They tease their upcoming live webinar on April 28th, which will focus on how sponsors can detect and prevent fraud in clinical trials. Expect real-world insights, early intervention strategies, and conversations that go beyond theory—because preventing fraud starts long before the red flags.

This isn’t your typical compliance chat. It’s a thoughtful, back-and-forth series that reflects how diverse perspectives can create stronger, smarter research environments.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Guardant Health’s recent $292 million victory against Natera in a false advertising lawsuit sets a critical precedent for the biotech industry, highlighting the severe consequences of misleading claims. This case is a wake-up call for drug and device companies navigating complex FDA and FTC regulations. False advertising not only misleads stakeholders but also exposes companies to significant financial losses and regulatory scrutiny.

Compliance officers and marketers must work together to ensure promotional materials are accurate, legally sound, and fully substantiated. Your PRC team should include both regulatory experts and legal professionals to verify claims, substantiate benefits, and avoid exaggerations. The cost of non-compliance can far exceed the effort required to get it right.

At Kulkarni Law Firm, we help companies mitigate advertising risks and stay compliant. Subscribe to our podcast for practical insights, and contact us to safeguard your organization’s reputation and bottom line. What steps has your company taken to audit its advertising practices? Share your thoughts with us!

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Darshan Kulkarni and Edye Edens discuss the critical role of data privacy in clinical trial site acquisitions. While privacy concerns can seem daunting, they don’t have to be a dealbreaker if managed correctly. The key is understanding whether privacy laws like HIPAA apply, ensuring the site is already handling data compliance well, and putting safeguards in place to mitigate risks. Investors should conduct thorough due diligence to assess the site's current privacy practices before the merger or acquisition.

One major misconception is that HIPAA always applies to clinical trial data. In reality, properly anonymized trial data often falls outside its scope, though certain patient records may still be regulated. Beyond HIPAA, state-specific laws such as the California Consumer Privacy Act (CCPA) and disease-specific privacy regulations (e.g., HIV, weight loss treatments) add layers of complexity. Additionally, compliance risks arise when acquiring companies use AI-driven tools, as AI itself is facing lawsuits over privacy violations.

A smart approach to privacy in M&A involves firewalling sensitive data whenever possible—if an acquiring company doesn’t need direct access to regulated data, it should avoid handling it altogether. Investors should also consider risks tied to telemedicine regulations, patient communications (TCPA, CAN-SPAM), and wiretapping laws in certain states. The goal is to minimize exposure while maintaining operational efficiency.

Ultimately, data privacy in clinical trial acquisitions is about proactive risk management. Understanding the regulatory landscape, setting clear boundaries around data access, and ensuring compliance with both federal and state laws can help investors navigate these challenges. If you’re considering acquiring a clinical trial site and want to safeguard your investment, reach out to us to discuss your privacy strategy.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The FDA you designed your protocol around may no longer exist. In this episode, Darshan Kulkarni breaks down why clinical researchers, regulatory attorneys, and promotional review teams need to pay attention—now.

With mass layoffs, frozen guidances, and a reorganization shaking CDER and CBER to their core, trial timelines, IRB reliance, and even legal interpretations are in flux. Marketing teams are flying blind with the FDA’s communications division gutted and post-Loper Bright challenges looming large.

Darshan outlines urgent next steps:
 ✔️ Rethink your submission timelines
 ✔️ Reassess your SOPs for oversight and reporting
 ✔️ Update your promotional risk strategy—especially in digital

If you're in life sciences and relying on yesterday’s FDA to approve tomorrow’s innovation, it’s time to rethink.

Reach out to the Kulkarni Law Firm—we specialize in compliance during regulatory chaos.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The FDA is facing unprecedented turmoil—staff cuts, a sweeping reorganization, and political interference are undermining its ability to safeguard public health. Former agency leaders are raising red flags, with one likening the situation to "flat earthers taking over NASA." With vaccine data access becoming politicized, stem cell oversight potentially weakening, and the user fee system in jeopardy, startups and pharma companies must treat this not as a minor policy shift but as a major compliance crisis. If you're not already reassessing your regulatory strategy, you're falling behind.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode, Kate Woods and Darshan Kulkarni discussed the shift from employer-sponsored health insurance to individual responsibility, a transition accelerated by policy changes and rising healthcare costs. Traditionally, employer-provided insurance has been the backbone of the U.S. healthcare system, but evolving regulations, including the Affordable Care Act (ACA), have made individual plans more accessible. This shift has given employees greater flexibility but also placed the burden of navigating complex insurance options on them, often without sufficient guidance.

One key development in this transition is the rise of Individual Coverage Health Reimbursement Arrangements (ICHRA), which allow employers to fund employees' insurance plans rather than providing direct coverage. While this model expands consumer choice, it also raises concerns about decision fatigue and potential financial risks, especially for younger employees who may prioritize lower premiums over comprehensive coverage. As the workforce becomes more mobile and remote work grows, the demand for personalized, portable health coverage is likely to increase.

The discussion also explored the role of AI and digital tools in simplifying healthcare decision-making. AI-powered platforms can assess consumer needs, predict potential risks, and recommend tailored insurance plans. However, while these tools offer convenience and efficiency, they also introduce risks related to bias, transparency, and over-reliance on automated decision-making. Without proper safeguards, employees may make uninformed choices based on incomplete or misleading AI-generated recommendations.

Both Kate and Darshan emphasized the importance of balancing technology with human expertise in healthcare decisions. While AI can streamline processes, it cannot fully replace the nuanced understanding of a skilled advisor. As the healthcare landscape continues to evolve, education, transparency, and regulatory oversight will be critical to ensuring that individuals can make informed choices without unintended consequences.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

When mergers and acquisitions intersect with clinical trials, due diligence becomes a crucial step in ensuring a successful transition. In this insightful discussion, Darshan Kulkarni and Edye Edens explore the key legal and operational considerations when acquiring or merging with clinical research entities, including sponsors, sites, and CROs.

A major focus of the conversation is understanding the risks associated with clinical trial sites. Many private equity investors are actively looking to acquire research sites, but without proper planning, these deals can present significant challenges. One of the biggest concerns is the departure of key personnel—often the very individuals who understand how the site operates. If a site owner exits without a succession plan, the entire operation could be at risk. Investors must assess whether there are trained personnel in place to sustain operations.

Ownership structure is another critical factor. The MSO (Management Services Organization) model is commonly used in healthcare acquisitions, but not all clinical research sites are structured this way. Some investors may assume that site acquisitions function like medical practice acquisitions, which can lead to compliance and operational gaps. Additionally, many site owners have handshake agreements with principal investigators (PIs) rather than formal contracts, posing risks when it comes to continuity and regulatory compliance.

From an operational standpoint, investors and sponsors need to evaluate where a site stands in its progression—its infrastructure, ability to handle feasibility audits, and experience in running trials. Conducting a thorough review of contracts, policies, and procedures is crucial. Beyond the high-level strategic risks, a deeper, on-the-ground audit of compliance and operational readiness is necessary to avoid unforeseen liabilities.

This discussion highlights the complexity of due diligence in clinical trial acquisitions. While this conversation only scratches the surface, it underscores the importance of a comprehensive review process. Investors, sponsors, and site owners must collaborate with legal and compliance experts to navigate these challenges effectively.

For a deeper dive into these issues, watch the full discussion or reach out to Kulkarni Law Firm for guidance.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Today’s episode is a wake-up call for pharma marketers launching telehealth campaigns. If you're using AI voice assistants or call automation tools in your outreach, you could be stepping into a legal minefield under California’s privacy law (CCPA & CIPA).

Your telehealth campaign reflects your brand—don’t let privacy lawsuits define it. Contact the Kulkarni Law Firm for a legal review of your telehealth tools to ensure compliance and protect your reputation.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode, Darshan Kulkarni explores an important yet often overlooked question—what happens after a clinical trial ends? While much focus is placed on clinical trials as a care option, the conversation shifts to the opportunities that exist for research-related resources post-trial.

Darshan is joined by:

• Lorri Warren, Program Director of the MedSurplus Alliance at the Task Force for Global Health, which focuses on improving healthcare systems and managing medical product donations.
• Donna Libretti Cooke, a consultant for Kits4Life, who formerly worked at Bayer and helped implement the Kits4Life initiative.
• Greg Folks, Chair of the Kits4Life Advisory Council, who has over 30 years of experience in clinical research, particularly from the site perspective.

The discussion highlights how clinical trial sites often accumulate surplus medical supplies and equipment, which are typically destroyed due to logistical and liability concerns. The Kits4Life initiative, built within the MedSurplus Alliance, aims to redirect these valuable resources to humanitarian efforts rather than letting them go to waste.

Greg shares how the idea stemmed from the realization that research sites were discarding perfectly usable, medical-grade supplies. Donna discusses the legal and compliance challenges faced by pharmaceutical companies in supporting such donations, emphasizing how structured donation agreements and liability protections help overcome these concerns. Lorri provides insights into how the MedSurplus Alliance facilitates these large-scale donations through vetted organizations to ensure compliance and proper distribution.

The episode underscores the importance of structured donation systems that allow surplus clinical trial supplies to benefit underserved healthcare communities, turning research into an ongoing care option even after a trial has concluded.

Support the show

www.kulkarnilawfirm.com